164 related articles for article (PubMed ID: 18403937)
1. Increased soluble IL-2 receptor levels during interferon and ribavirin treatment are associated with a good response in genotype 2a/2b patients with chronic hepatitis C.
Abe S; Narita R; Matsuhashi T; Oto T; Tabaru A; Otsuki M
Eur J Gastroenterol Hepatol; 2008 May; 20(5):373-8. PubMed ID: 18403937
[TBL] [Abstract][Full Text] [Related]
2. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
4. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone.
Saracco G; Ciancio A; Olivero A; Smedile A; Roffi L; Croce G; Colletta C; Cariti G; Andreoni M; Biglino A; Calleri G; Maggi G; Tappero GF; Orsi PG; Terreni N; Macor A; Di Napoli A; Rinaldi E; Ciccone G; Rizzetto M
Hepatology; 2001 Jul; 34(1):133-8. PubMed ID: 11431744
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C.
Murata K; Yamamoto N; Kawakita T; Saito Y; Yamanaka Y; Sugimoto K; Shiraki K; Nakano T; Tameda Y
Hepatogastroenterology; 2005; 52(62):547-51. PubMed ID: 15816475
[TBL] [Abstract][Full Text] [Related]
6. Monocyte-derived dendritic cells in children with chronic hepatitis C: correlation with interferon and ribavirin therapy.
Khedr MA; E Behairy B; Hussein ME; Marei AM; Nage SA; Zakaria HM
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1170-4. PubMed ID: 26148246
[TBL] [Abstract][Full Text] [Related]
7. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load.
Izumi N; Asahina Y; Kurosaki M; Uchihara M; Nishimura Y; Inoue K; Ueda K; Tsuchiya K; Hamano K; Itakura J; Miyake S
Intervirology; 2004; 47(2):102-7. PubMed ID: 15192274
[TBL] [Abstract][Full Text] [Related]
9. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
Di Bisceglie AM; Ghalib RH; Hamzeh FM; Rustgi VK
J Viral Hepat; 2007 Oct; 14(10):721-9. PubMed ID: 17875007
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
11. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
[TBL] [Abstract][Full Text] [Related]
12. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
13. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
14. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
Yenice N; Mehtap O; Gümrah M; Arican N
Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients.
el-Zayadi A; Selim O; Haddad S; Simmonds P; Hamdy H; Badran HM; Shawky S
Ital J Gastroenterol Hepatol; 1999; 31(6):472-5. PubMed ID: 10575565
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4.
Zekri AR; Haleem HA; Esmat GE; Bahnassy AA; El-Din HM; Hafez MM; Sharaby AF; Sharaf H; Zakaria MS
J Viral Hepat; 2007 Jul; 14(7):468-77. PubMed ID: 17576388
[TBL] [Abstract][Full Text] [Related]
18. Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads.
Enomoto M; Nishiguchi S; Kohmoto M; Tamori A; Habu D; Takeda T; Seki S; Shiomi S
J Viral Hepat; 2004 Sep; 11(5):448-54. PubMed ID: 15357651
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
Cramp ME; Rossol S; Chokshi S; Carucci P; Williams R; Naoumov NV
Gastroenterology; 2000 Feb; 118(2):346-55. PubMed ID: 10648463
[TBL] [Abstract][Full Text] [Related]
20. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
